Mary Szela Net Worth

The estimated Net Worth of Mary T Szela is at least $3.99 Million dollars as of 14 December 2011. Ms. Szela owns over 53,201 units of Coherus BioSciences stock worth over $2,817,627 and over the last 12 years she sold CHRS stock worth over $984,580. In addition, she makes $187,284 as Independent Director at Coherus BioSciences.

Ms. Szela CHRS stock SEC Form 4 insider trading

Mary has made over 16 trades of the Coherus BioSciences stock since 2007, according to the Form 4 filled with the SEC. Most recently she exercised 53,201 units of CHRS stock worth $2,853,170 on 14 December 2011.

The largest trade she’s ever made was exercising 53,201 units of Coherus BioSciences stock on 14 December 2011 worth over $2,853,170. On average, Mary trades about 3,655 units every 41 days since 2007. As of 14 December 2011 she still owns at least 172,543 units of Coherus BioSciences stock.

You can see the complete history of Ms. Szela stock trades at the bottom of the page.

Mary Szela biography

Mary T. Szela is Independent Director of the Coherus BioSciences, Inc. In January 2018, Ms. Szela was named Chief Executive Officer and President of Surefire Medical, Inc. (TriSalus LifeSciences) and currently serves on its board of directors. Mats L. Wahlström, a member of our Board of Directors, currently serves as Chairman of Surefire Medical, Inc. (TriSalus LifeSciences). From January 2016 to November 2016, Ms. Szela served as Chief Executive Officer of Aegerion Pharmaceuticals, Inc. and served on its board of directors. In November 2016, Aegerion Pharmaceuticals, Inc. merged with QLT Inc. to form Novelion Therapeutics Inc., where, until November 2017, Ms. Szela served as Chief Executive Officer and as a member of its board of directors. Ms. Szela served as the Chief Executive Officer of Melinta Therapeutics, Inc., an antibiotic development company, from April 2013 to August 2015. She has also served on the board of directors of Kura Oncology, Inc. since October 2018, Melinta from January 2013 to August 2015, Receptos, Inc. from June 2014 to July 2015, Novo Nordisk from March 2014 to March 2017 and Suneva Medical, Inc. from July 2012 to 2017. Previously, Ms. Szela joined Abbott Laboratories in 1987 and held several leadership positions, including Senior Vice President of Global Strategic Marketing from January 2010 to May 2012 and Senior Vice President of U.S. Pharmaceuticals from September 2008 to December 2009. Prior to Abbott, Ms. Szela worked for the University of Illinois Hospital. Ms. Szela earned a B.S. in Nursing and an M.B.A. from the University of Illinois.

What is the salary of Mary Szela?

As the Independent Director of Coherus BioSciences, the total compensation of Mary Szela at Coherus BioSciences is $187,284. There are 10 executives at Coherus BioSciences getting paid more, with Dennis Lanfear having the highest compensation of $3,919,780.

How old is Mary Szela?

Mary Szela is 56, she’s been the Independent Director of Coherus BioSciences since 2014. There are 9 older and 3 younger executives at Coherus BioSciences. The oldest executive at Coherus BioSciences, Inc. is Barbara Finck, 71, who is the Chief Medical Officer.

What’s Mary Szela’s mailing address?

Mary’s mailing address filed with the SEC is C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.

Insider trading at Coherus BioSciences

Over the last 5 years, insiders at Coherus BioSciences have traded over $60,488,230 worth of Coherus BioSciences stock and bought 590,889 units worth $7,977,002 . The most active insider traders include Llc Fmr, James Healy, and August J. Troendle. On average, Coherus BioSciences executives and independent directors trade stock every 20 days with the average trade being worth of $634,535. The most recent stock trade was executed by Jean Frederic Viret on 18 October 2019, trading 1,388 units of CHRS stock currently worth $26,400.

What does Coherus BioSciences do?

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

What does Coherus BioSciences’s logo look like?

Complete history of Ms. Szela stock trades at Alimera Sciences, Coherus BioSciences, Novelion Therapeutics, and Abbott Laboratories

Coherus BioSciences executives and stock owners

Coherus BioSciences executives and other stock owners filed with the SEC include:

• Dennis Lanfear, Chairman of the Board, President, Chief Executive Officer
• Vincent Anicetti, Chief Operating Officer
• Barbara Finck, Chief Medical Officer
• Jean-Frederic Viret, Chief Financial Officer
• Vladimir Vexler, Chief Scientific Officer
• Peter Watler, Chief Technology Officer
• Samuel Nussbaum, Independent Director
• Mats Wahlstrom, Lead Independent Director
• V. Bryan Lawlis, Independent Director
• James Healy, Independent Director
• Mary Szela, Independent Director
• Ali Satvat, Independent Director
• Christos Richards, Director
• Darlene Horton, Chief Medical and Regulatory Affairs Officer
• Thomas Fitzpatrick, Chief Legal Officer
• Alan C. Herman, Chief Scientific Officer
• August J. Troendle, Director
• Llc Fmr, 10% owner
• Biosimilar L.P.Kkr Biosimil…,
• Eli & Co Lilly Ventures Fun…,
• Sankyo Company, Ltd Daiichi,